Patent intelligence · EP
EP 2662386
Antikörper, die an PLAC1 binden und die Wechselwirkung zwischen PLAC1 und FGF7 inhibieren
Antikörper, die an PLAC1 binden und die Wechselwirkung zwischen PLAC1 und FGF7 inhibieren
Patent details — EP 2662386
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Nov 13, 2013
- Expiration
- Nov 8, 2033
- Applicant
- BIONTECH AG [DE]
- CPC classes
- A61K 39/ 00 A I
Quick answer
EP 2662386 (Antikörper, die an PLAC1 binden und die Wechselwirkung zwischen PLAC1 und FGF7 inhibieren) is held by BIONTECH AG [DE]. Status: granted. Granted Nov 13, 2013. Expires Nov 8, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIONTECH AG [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 39/ 00 A I
More from BIONTECH AG [DE]
Related pharmaceutical patents in our USPTO index.
-
AU 2022206771
Drug conjugates comprising antibodies against Claudin 18.2
granted -
EP 3791896
KOMBINATIONSTHERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS
granted -
LT 3254695
COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted -
EP 3708579
CLAUDIN-6-SPEZIFISCHE IMMUNREZPTOREN UND T-ZELL-EPITOPE
granted -
HR P20200591
ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6)
granted -
US 2020199221
ANTIBODIES USEFUL IN CANCER DIAGNOSIS
granted -
WO 2020095183
COMBINAISON POUR LE TRAITEMENT DU CANCER
granted -
US 2019076525
THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted
Frequently asked questions
What is US patent 2662386?
EP 2662386 (Antikörper, die an PLAC1 binden und die Wechselwirkung zwischen PLAC1 und FGF7 inhibieren) is held by BIONTECH AG [DE]. Status: granted. Granted Nov 13, 2013. Expires Nov 8, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 2662386?
BIONTECH AG [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does EP 2662386 expire?
Our index shows an expiration date of Nov 8, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.